Comparison of serum hemagglutinin and neuraminidase inhibition antibodies after 2010-2011 trivalent inactivated influenza vaccination in healthcare personnel

Open Forum Infectious Diseases

Volumn 2, Issue 1, 2015, Pages

  Laguio Vila, Maryrose R ^a   Thompson, Mark G ^b   Reynolds, Sue ^b   Spencer, Sarah M ^b   Gaglani, Manjusha ^c   Naleway, Allison ^d   Ball, Sarah ^e   Bozeman, Sam ^e   Baker, Steven ^a   Martínez Sobrido, Luis ^a   Levine, Min ^b   Katz, Jackie ^b   Fry, Alicia M ^b   Treanor, John J ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^d CENTER FOR HEALTH RESEARCH   (United States)

^e ABT ASSOCIATES   (United States)

Author keywords

Antibody; Hemagglutinin inhibition; Influenza; Neuraminidase inhibition; Vaccine

Indexed keywords

ANTIBODY; HEMAGGLUTININ; HEMAGGLUTININ INHIBITION ANTIBODY; INFLUENZA VACCINE; LECTIN; NEURAMINIDASE INHIBITION ANTIBODY; SIALIDASE; TRIVALENT INACTIVATED INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTHROPOMETRY; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CROSS PROTECTION; DATA PROCESSING; FEMALE; GEOMETRY; HEALTH CARE PERSONNEL; HUMAN; IMMUNOGENICITY; INFECTION RISK; INFLUENZA; INFLUENZA A VIRUS (H3N2); INFLUENZA A VIRUS (H5N1); INFLUENZA VACCINATION; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84978328535     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofu115     Document Type: Article

References (33)

1. Schwartz B, Hinman A, Abramson J, et al. Universal influenza vaccination in the United States: are we ready? J Infect Dis 2006; 194:S147-54.
2. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and costbenefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000; 284:1655-63.
3. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003; 21:1776-9.
4. Lambre CR, Terzidis H, Greffard A, et al. Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates. J Immunol Methods 1990; 135:49-57.
5. Cate TR, Rayford Y, Nino D, et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 2010; 28:2076-8.
6. Gavrilov V, Orekov T, Alabanza C, et al. Influenza virus-like particles as a new tool for vaccine immunogenicity testing. J Virol Methods 2011; 173:364-73.
7. Gaglani M, Spencer S, Ball S, et al. Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine. J Infect Dis 2014; 209:1705-14.
8. Johansson BE, Kilbourne ED. Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competion. J Virol 1993; 67:5721-3.
9. De Bruijn IA, Remarque EJ, Jol-van der Zijde CM, et al. Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. J Infect Dis 1999; 179:31-6.
10. Martinez-Sobrido L, Cadagan R, Steel J, et al. Hemagglutininpseudotyped GFP-expressing influenza viruses for the detection of influenza virus neutralizing antibodies. J Virol 2010; 84:2157-63.
11. Baker SF, Guo H, Albrecht RA, et al. Protection against lethal influenza with a viral mimic. J Virol 2013; 87:8591-605.
12. Chen Z, Kadowaki S, Yoshikawa H, et al. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine 2000; 18:3214-22.
13. Sandbulte MR, Westgeest KB, Gao J, et al. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proc Natl Acad Sci U S A 2011; 108:20748-53.
14. Couch RB, Atmar RL, Keitel WA, et al. Randomized comparative study of the serum antihemagglutinin and neuraminidase antibody responses to six licensed trivalent influenza vaccines. Vaccine 2012; 31:190-5.
15. Payment P, Trudel M. Methods and Techniques in Virology. New York: Marcel Dekker, 1993.
16. Murphy BR, Kasel JA, Chanock RM. Association of serum antineuraminidase antibody with resistance to influenza in man. N Engl J Med 1972; 286:1329-32.
17. Xie H, Li XJ, Gao J, et al. Revisiting the 1976 "swine flu" vaccine clinical trials: cross-reactive hemaggutinin and neuraminidase antibodies and their role in protection against the 2009 H1N1 pandemic virus in mice. Clin Infect Dis 2011; 53:1179-87.
18. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24:1159-69.
19. Keitel WA, Atmar RL, Cate TR, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006; 166:1121-7.
20. Falsey AR, Treanor JJ, Tornieporth N, et al. Superior immunogenicity of high dose influenza vaccine compared with standard influenza vaccine in adults > 65 years of age: a randomized double-blinded controlled phase 3 trial. J Infect Dis 2008; 200:172-80.
21. Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361:1945-52.
22. Marcelin G, Bland HM, Negovetich NJ, et al. Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner. J Infect Dis 2010; 202:1634-8.
23. Gardner EM, Bernstein ED, Dran S, et al. Characterization of antibody responses to annual influenza vaccination over four years in a healthy elderly population. Vaccine 2001; 19:4610-7.
24. Fisher BM, Van Bockern J, Hart J, et al. Pandemic influenza A H1N1 infection versus vaccination: a cohort study comparing immune responses in pregnancy. PLoS One 2012; 7:e33048.
25. Uhr JW, Moller G. Regulatory effect of antibody on the immune response. Adv Immunol 1968; 8:81-127.
26. Monto AS, Kendal AP. Effect of neuraminidase antibody on Hong Kong influenza. Lancet 1973; 7804:623-5.
27. Clements ML, Betts RF, Tierney EL, et al. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986; 24:157-60.
28. Couch RB, Atmar RL, Franco LM, et al. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis 2013; 207:974-81.
29. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353:1363-73.
30. Johansson BE, Bucher DJ, Kilbourne ED. Purified influenza virus hemagluttinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J Virol 1989; 63:1239-46.
31. Martinez C, del Rio L, Partela A, et al. Evolution of the influenza virus neuraminidase gene during drift of the N2 subtype. Virology 1983; 130:539-45.
32. Sandbulte MR, Jimenez GS, Boon AC, et al. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007; 4:e59.
33. Westgeest KB, De Graaf M, Fourment M, et al. Genetic evolution of the neuraminidase of influenza A (H3N2) viruses from 1968 to 2009 and its correspondence to haemagglutinin evolotion. J Gen Virol 2012; 93:1996-2007.